Recombinant Human IL-29/IFN-lambda 1 Protein

(NS0-expressed)

Carrier Free

Catalog # Availability Size / Price Qty
1598-IL-025/CF

With Carrier

Catalog # Availability Size / Price Qty
1598-IL-025
Best Seller
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (44)
FAQs
Reviews (3)

Recombinant Human IL-29/IFN-lambda 1 Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED50 for this effect is 1-5 ng/mL.
Source
Mouse myeloma cell line, NS0-derived human IL-29/IFN-lambda 1 protein
Gly20-Thr200, with a C-terminal 10-His tag
Accession #
N-terminal Sequence
Analysis
Gly20
Predicted Molecular Mass
21.4 kDa
SDS-PAGE
26-35 kDa, reducing conditions

Product Datasheets

You must select a language.

x

1598-IL (with carrier)

You must select a language.

x

1598-IL/CF (carrier free)

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1598-IL

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

1598-IL/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IL-29/IFN-lambda 1

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta ) and a novel IL-28 receptor  alpha (IL‑28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory region of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively.

References
  1. Vilcek, J. (2003) Nature Immunol. 4:8.
  2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
  3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.
Long Name
Interleukin 29
Entrez Gene IDs
282618 (Human)
Alternate Names
cytokine Zcyto21; IFNL1; IFN-lambda 1; IFN-lambda-1; IL29; IL-29; interferon lambda-1; interferon, lambda 1; interleukin 29 (interferon, lambda 1); interleukin-29; ZCYTO21

Citations for Recombinant Human IL-29/IFN-lambda 1 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

44 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Airway epithelial CD47 plays a critical role in inducing influenza virus-mediated bacterial super-infection
    Authors: Moon, S;Han, S;Jang, IH;Ryu, J;Rha, MS;Cho, HJ;Yoon, SS;Nam, KT;Kim, CH;Park, MS;Seong, JK;Lee, WJ;Yoon, JH;Chung, YW;Ryu, JH;
    Nature communications
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Oral Antiviral Defense: Saliva- and Beverage-like Hypotonicity Dynamically Regulate Formation of Membraneless Biomolecular Condensates of Antiviral Human MxA in Oral Epithelial Cells
    Authors: Sehgal, PB;Yuan, H;Centone, A;DiSenso-Browne, SV;
    Cells
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. The E3 ligase subunit FBXO45 binds the interferon-lambda receptor and promotes its degradation during influenza virus infection
    Authors: M Tsai, W Osman, J Adair, R ElMergawy, L Chafin, F Johns, D Farkas, A Elhance, J Londino, RK Mallampall
    The Journal of Biological Chemistry, 2022-11-13;0(0):102698.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Inhibiting Type I arginine methyltransferase activity promotes the T cell mediated antitumor immune response
    Authors: A Fedoriw, L Shi, S O'Brien, KN Smitheman, Y Wang, J Hou, C Sherk, S Rajapurkar, J Laraio, LJ Williams, C Xu, G Han, Q Feng, MT Bedford, L Wang, O Barbash, RG Kruger, P Hwu, HP Mohammad, W Peng
    Cancer Immunology Research, 2022-04-01;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Astrocyte Control of Zika Infection Is Independent of Interferon Type I and Type III Expression
    Authors: M Das, ML Smith, T Furihata, S Sarker, R O'Shea, KJ Helbig
    Biology, 2022-01-15;11(1):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2
    Authors: CF Hatton, RA Botting, ME Dueñas, IJ Haq, B Verdon, BJ Thompson, JS Spegarova, F Gothe, E Stephenson, AI Gardner, S Murphy, J Scott, JP Garnett, S Carrie, J Powell, CMA Khan, L Huang, R Hussain, J Coxhead, T Davey, AJ Simpson, M Haniffa, S Hambleton, M Brodlie, C Ward, M Trost, G Reynolds, CJA Duncan
    Nature Communications, 2021-12-07;12(1):7092.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Intracellular lipid droplet accumulation occurs early following viral infection and is required for an efficient interferon response
    Authors: EA Monson, KM Crosse, M Duan, W Chen, RD O'Shea, LM Wakim, JM Carr, DR Whelan, KJ Helbig
    Nature Communications, 2021-07-14;12(1):4303.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir
    Authors: C Medaglia, AC Zwygart, PJ Silva, S Constant, S Huang, F Stellacci, C Tapparel
    Microorganisms, 2021-06-01;9(6):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation
    Authors: HC Hawerkamp, A Domdey, L Radau, P Sewerin, P Oláh, B Homey, S Meller
    Arthritis Research & Therapy, 2021-05-21;23(1):144.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities
    Authors: M Hayn, M Hirschenbe, L Koepke, R Nchioua, JH Straub, S Klute, V Hunszinger, F Zech, C Prelli Boz, W Aftab, MH Christense, C Conzelmann, JA Müller, S Srinivasac, CM Stürzel, I Forne, S Stenger, KK Conzelmann, J Münch, FI Schmidt, D Sauter, A Imhof, F Kirchhoff, KMJ Sparrer
    Cell Reports, 2021-04-27;35(7):109126.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Human Intestinal Organoids Recapitulate Enteric Infections of Enterovirus and Coronavirus
    Authors: X Zhao, C Li, X Liu, MC Chiu, D Wang, Y Wei, H Chu, JP Cai, I Hau-Yee Ch, K Kak-Yuen W, J Fuk-Woo Ch, K Kai-Wang T, KY Yuen, J Zhou
    Stem Cell Reports, 2021-02-12;16(3):493-504.
    Species: Primate - C. aethiops
    Sample Types: Whole Cells
    Applications: Bioassay
  12. Interferon-&lambda Enhances the Differentiation of Naive B Cells into Plasmablasts via the mTORC1 Pathway
    Authors: M Syedbasha, F Bonfiglio, J Linnik, C Stuehler, D Wüthrich, A Egli
    Cell Rep, 2020-10-06;33(1):108211.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Heatr9 is an infection responsive gene that affects cytokine production in alveolar epithelial cells
    Authors: CJ Stairiker, M van Meurs, LG Leon, AA Brouwers-H, L Rijsbergen, YM Mueller, PD Katsikis
    PLoS ONE, 2020-07-17;15(7):e0236195.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Interferon-Dependent and Respiratory Virus-Specific Interference in Dual Infections of Airway Epithelia
    Authors: M Essaidi-La, J Geiser, S Huang, S Constant, L Kaiser, C Tapparel
    Sci Rep, 2020-06-24;10(1):10246.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  15. Dendritic cells-derived interferon-lambda1 ameliorated inflammatory bone destruction through inhibiting osteoclastogenesis
    Authors: Y Chen, Y Wang, R Tang, J Yang, C Dou, Y Dong, D Sun, C Zhang, L Zhang, Y Tang, Q Dai, F Luo, J Xu, S Dong
    Cell Death Dis, 2020-06-02;11(6):414.
    Species: Mouse
    Sample Types: In Vivo, Whole Cells
    Applications: Bioassay, In Vivo
  16. RIG-I-like receptor activation drives type I IFN and antiviral signaling to limit�Hantaan orthohantavirus replication
    Authors: AM Kell, EA Hemann, JB Turnbull, M Gale
    PLoS Pathog., 2020-04-24;16(4):e1008483.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  17. Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency
    Authors: JH Chung, SH Hong, N Seo, TS Kim, HJ An, P Lee, EC Shin, HM Kim
    Cytokine, 2019-08-31;125(0):154833.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Type III interferon signaling restricts enterovirus 71 infection of goblet cells
    Authors: C Good, AI Wells, CB Coyne
    Sci Adv, 2019-03-06;5(3):eaau4255.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  19. MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway
    Authors: H Xu, SJ Xu, SJ Xie, Y Zhang, JH Yang, WQ Zhang, MN Zheng, H Zhou, LH Qu
    Elife, 2019-02-08;8(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  20. REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1? Inflammatory Response in Active Ulcerative Colitis
    Authors: I Angelidou, A Chrysantho, A Mitsios, S Arelaki, A Arampatzio, K Kambas, D Ritis, V Tsironidou, I Moschos, V Dalla, D Stakos, G Kouklakis, I Mitroulis, K Ritis, P Skendros
    J. Immunol., 2018-04-30;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  21. A systematic approach to the development of a safe live attenuated Zika vaccine
    Authors: SS Kwek, S Watanabe, KR Chan, EZ Ong, HC Tan, WC Ng, MTX Nguyen, ES Gan, SL Zhang, KWK Chan, JH Tan, OM Sessions, M Manuel, J Pompon, C Chua, S Hazirah, K Tryggvason, SG Vasudevan, EE Ooi
    Nat Commun, 2018-03-12;9(1):1031.
    Species: Primate - Chlorocebus aethiops (African Green Monkey)
    Sample Types: Whole Cells
    Applications: Cell Culture
  22. Interferon lambda receptor 1 (IFNL1R) transcript is highly expressed in rhinovirus bronchiolitis and correlates with disease severity
    Authors: A Pierangeli, M Statzu, R Nenna, L Santinelli, L Petrarca, A Frassanito, M Gentile, G Antonelli, F Midulla, C Scagnolari
    J. Clin. Virol., 2018-03-10;102(0):101-109.
    Species: Human
    Sample Types: Whole Cells
    Applications: Stimulation
  23. IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling
    Authors: AA Obajemu, N Rao, KA Dilley, JM Vargas, F Sheikh, RP Donnelly, RS Shabman, EG Meissner, L Prokunina-, OO Onabajo
    J. Immunol., 2017-10-25;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  24. Organotypic models of type III interferon-mediated protection from Zika virus infections at the maternal-fetal interface
    Authors: J Corry, N Arora, CA Good, Y Sadovsky, CB Coyne
    Proc. Natl. Acad. Sci. U.S.A., 2017-08-07;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  25. Generation and characterization of interferon-lambda 1-resistant H1N1 influenza A viruses
    Authors: NA Ilyushina, VY Lugovtsev, AP Samsonova, FG Sheikh, NV Bovin, RP Donnelly
    PLoS ONE, 2017-07-27;12(7):e0181999.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  26. IFN-?4 potently blocks IFN-? signalling by ISG15 and USP18 in hepatitis C virus infection
    Authors: PS Sung, SH Hong, JH Chung, S Kim, SH Park, HM Kim, SK Yoon, EC Shin
    Sci Rep, 2017-06-19;7(1):3821.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  27. IFN-?1 with Th17 axis cytokines and IFN-? define different subsets in systemic lupus erythematosus (SLE)
    Authors: V Oke, S Brauner, A Larsson, J Gustafsson, A Zickert, I Gunnarsson, E Svenungsso
    Arthritis Res. Ther., 2017-06-15;19(1):139.
    Species: Human
    Sample Types: Serum
    Applications: ELISA (Standard)
  28. Interferon (IFN)-? is a potential mediator in lupus nephritis
    Authors: Iva Gunnarsson
    Lupus Sci Med, 2016-11-22;3(1):e000170.
    Species: Human
    Sample Types: Serum
    Applications: ELISA (Standard)
  29. Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling
    Nat. Med., 2016-11-14;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  30. Dengue virus infection induces interferon-lambda1 to facilitate cell migration
    Sci Rep, 2016-07-26;6(0):24530.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  31. Antagonistic antiviral activity between IFN-lambda and IFN-alpha against lethal Crimean-Congo hemorrhagic fever virus in vitro.
    Authors: Bordi L, Lalle E, Caglioti C, Travaglini D, Lapa D, Marsella P, Quartu S, Kis Z, Arien K, Huemer H, Meschi S, Ippolito G, Di Caro A, Capobianchi M, Castilletti C
    PLoS ONE, 2015-02-18;10(2):e0116816.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  32. Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth.
    Authors: Ding S, Khoury-Hanold W, Iwasaki A, Robek M
    PLoS Biol, 2014-01-07;12(1):e1001758.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  33. IL-27, a cytokine, and IFN-lambda1, a type III IFN, are coordinated to regulate virus replication through type I IFN.
    Authors: Cao Y, Zhang R, Zhang W, Zhu C, Yu Y, Song Y, Wang Q, Bai L, Liu Y, Wu K, Wu J
    J Immunol, 2013-12-11;192(2):691-703.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  34. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
    Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
    Nature, 2012-07-26;487(7408):505-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  35. Dobrava-Belgrade hantavirus from Germany shows receptor usage and innate immunity induction consistent with the pathogenicity of the virus in humans.
    Authors: Popugaeva E, Witkowski PT, Schlegel M, Ulrich RG, Auste B, Rang A, Kruger DH, Klempa B
    PLoS ONE, 2012-04-24;7(4):e35587.
    Species: Human
    Sample Types: Whole Cells
    Applications: Control
  36. Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-lambda genes produced anti-tumour effects.
    Authors: Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M
    Br. J. Cancer, 2011-09-27;105(9):1302-12.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  37. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN-lambda) in cutaneous lupus erythematosus.
    Authors: Zahn S, Rehkamper C, Kummerer BM, Ferring-Schmidt S, Bieber T, Tuting T, Wenzel J
    J. Invest. Dermatol., 2010-08-19;131(1):133-40.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  38. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines.
    Authors: Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K
    Genes Immun., 2009-10-01;10(8):702-14.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  39. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages.
    Authors: Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P
    Int. J. Cancer, 2009-07-15;125(2):367-73.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  40. Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chain.
    Authors: Bin L, Howell MD, Kim BE, Hall CF, Streib JE, Leung DY
    J. Allergy Clin. Immunol., 2009-07-03;124(2):270-7, 277.e1.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  41. Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps.
    Authors: Kato A, Peters A, Suh L, Carter R, Harris KE, Chandra R, Conley D, Grammer LC, Kern R, Schleimer RP
    J. Allergy Clin. Immunol., 2008-04-14;121(6):1385-92, 1392.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  42. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes.
    Authors: Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD, Sabat R
    J. Leukoc. Biol., 2008-02-15;83(5):1181-93.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  43. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells.
    Authors: Kato A, Favoreto S, Avila PC, Schleimer RP
    J. Immunol., 2007-07-15;179(2):1080-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  44. Biological activity of interleukins-28 and -29: comparison with type I interferons.
    Authors: Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M
    Cytokine, 2005-07-21;31(2):109-18.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human IL-29/IFN-lambda 1 Protein

Average Rating: 4 (Based on 3 Reviews)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human IL-29/IFN-lambda 1 Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human IL-29/IFN-lambda 1 Protein
By Anonymous on 12/03/2018
Application: CellProlif

Recombinant Human IL-29/IFN-lambda 1 Protein
By Anonymous on 06/01/2018
Application: Immunoassay Standard

The recombinant IFN-lambda served as the calibration material in an ELISA which used MAB15981 and BAF1598 as matched pair antibodies.


Recombinant Human IL-29/IFN-lambda 1 Protein
By Anonymous on 12/01/2017
Application: In vitro bioactivity in cell culture